NCT03420014 2023-10-10
FIBROSARC US
Philogen S.p.A.
Phase 2 Unknown
Clinical Trials
11 trialsNCT05448820 2023-09-21
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Unknown
NCT05138146 2021-11-30
A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2 Unknown
NCT03294577 2021-01-15
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
BeyondSpring Pharmaceuticals Inc.
Phase 3 Unknown
NCT03002805 2019-08-19
CBT-1® in Combination With Doxorubicin in Patients With Metastatic, Unresectable Sarcomas Who Previously Progressed on Doxorubicin
CBA Research
Phase 1 Unknown
NCT01204801 2015-09-24
Medifocus301
Medifocus, Inc.
Phase 3 Unknown
NCT01715168 2015-01-15
A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
Azaya Therapeutics, Inc.
Phase 1 Unknown
NCT00718484 2014-01-30
PICASSO
Alaunos Therapeutics
Phase 2 Unknown
NCT00294996 2009-03-31
Trial of Myocet in Metastatic Breast Cancer
Sopherion Therapeutics
Phase 3 Unknown
NCT00250874 2005-11-08
Myocet, Docetaxel & Trastuzumab as 1st Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer
Zeneus Pharma
Phase 2 Unknown
NCT00002318 2005-06-24
A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
NIH AIDS Clinical Trials Information Service
Phase 3 Unknown